Collaborations
Key partners in our science
Veana Therapeutics partners with leading medical research institutions to advance the development of our VIMO technology platform.
The company has an extensive research collaboration with the Earle A. Chiles Research Institute of the Providence Cancer Institute. Veana has also established strong working relationships with a world-class group of research and clinical collaborators at the University of Washington and at Legacy Health- Legacy Research Institute to test and develop the next generation of VIMO anti-cancer therapies.
The University of Washington (UW) is one of the world’s preeminent public universities. Through its Office of Research, UW creates an outstanding climate of support for researchers, broadly enabling stellar research advances.
Veana Therapeutics and the University of Washington have entered into a strategic research collaboration that includes a Phase 1 study of Veana’s lead compound, VT-101 in combination with trastuzumab in metastatic HER2+ breast cancer patients.
The Legacy Health - Legacy Research Institute (LRI) provides a resource-rich environment that supports translational research that has direct application to improving patient care. LRI provides comprehensive clinical trials management in both inpatient and outpatient environments.
Veana has teamed up with Legacy Research Institute for an NIH-sponsored research project that focuses on the pre-clinical evaluation of VT-101 in combination with anti-Her2/neu (trastuzumab) in the treatment of Her2/neu+ Breast Cancer.
The Earle A. Chiles Research Institute is a world-class research facility located within Providence Cancer Institute dedicated to discovering curative therapies for cancer patients. Its main area of investigation is cancer immunotherapy, a specialized field of study focused on harnessing the innate power of the immune system to cure cancer.
Providence Cancer Institute, through its Earle A. Chiles Research Institute has been a strong strategic partner even before the company’s inception as a spin-off from the Earle A. Chiles Research Institute in 2012. Providence and Veana Therapeutics conducted a Phase 1 basket trial to assess the safety and efficacy of VT-101in patients with advanced cancers.
Interested in partnering with Veana Therapeutics?
Veana Therapeutics works closely with researchers and clinicians at leading universities, government institutions, and medical research centers. Researchers interested in a pre-clinical or clinical collaboration with Veana Therapeutics are welcome to contact us.